Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Didier Meulendijks"'
Autor:
Shunsuke Kondo, Yuki Katsuya, Kan Yonemori, Keiko Komuro, Masatoshi Sugeno, Toshio Kawata, Dana Ghiorghiu, Didier Meulendijks, Noboru Yamamoto
Publikováno v:
Cancer Treatment and Research Communications, Vol 39, Iss , Pp 100809- (2024)
Introduction: We aimed to assess the safety, pharmacokinetic profile, and antitumor activity of adavosertib monotherapy in Japanese patients with advanced solid tumors. Materials and methods: This was a single-center, open-label, phase I study with t
Externí odkaz:
https://doaj.org/article/c5e3b71ea3544fcba7e6ccf11b726a69
Autor:
Bart A.W. Jacobs, Maarten J. Deenen, Markus Joerger, Hilde Rosing, Niels deVries, Didier Meulendijks, Annemieke Cats, Jos H. Beijnen, Jan H.M. Schellens, Alwin D.R. Huitema
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 12, Pp 940-950 (2019)
Capecitabine is an oral prodrug of the anticancer drug 5‐fluorouracil (5‐FU). The primary aim of this study was to develop a pharmacokinetic model for capecitabine and its metabolites, 5′‐deoxy‐5‐fluorocytidine (dFCR), 5′‐deoxy‐5‐
Externí odkaz:
https://doaj.org/article/8300a5fe4be74766ad22f7c77488aab7
Autor:
Daniela Melchiorri, Jonas Bergh, Francesco Pignatti, Didier Meulendijks, Paula Hennik, Bjorg Bolstad, Luca Moscetti, Jorge Camarero, Filip Josephson, Maja Sommerfelt Grønvold, Jan Sjoberg, Mihaela Botezatu, Jorn Mulder, Ana Trullas Jimeno, Nikolaos Zafiropoulos, Harald Enzmann
Publikováno v:
ESMO Open, Vol 5, Iss 4 (2020)
The therapeutic landscape in the treatment of advanced/metastatic renal cell cancer has evolved over the last 2 years with the advent of immune checkpoint inhibitors. In 2018 and 2019, marketing authorisations valid throughout the European Union were
Externí odkaz:
https://doaj.org/article/7a7953d10b004678ab44dca70ec3f5f2
Autor:
Yang Yu, kyriaki Tzogani, Tomas Salmonson, Christian Gisselbrecht, Francesco Pignatti, Didier Meulendijks, Carla Herberts, Paula Hennik, Remy Verheijen, Torunn Wangen, Gro Dahlseng Håkonsen, Torny Kaasboll, Marianne Dalhus, Bjorg Bolstad
Publikováno v:
ESMO Open, Vol 4, Iss 6 (2019)
On 18 September 2017, a marketing authorisation valid through the European Union (EU) was issued for midostaurin in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy and for patients i
Externí odkaz:
https://doaj.org/article/4ca5e08d64734ec4aef2f64b34b02f26
Autor:
Femke M. de Man, G.D. Marijn Veerman, Esther Oomen-de Hoop, Maarten J. Deenen, Didier Meulendijks, Caroline M.P.W. Mandigers, Marcel Soesan, Jan H.M. Schellens, Esther van Meerten, Teun van Gelder, Ron H.J. Mathijssen
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 11 (2019)
Background: Capecitabine is generally dosed based on body surface area (BSA). This dosing strategy has several limitations; however, evidence for alternative strategies is lacking. Therefore, we analyzed the toxicity and effectiveness of fixed-dose c
Externí odkaz:
https://doaj.org/article/83660daccf0142229ea5b2375699afac
Publikováno v:
Tumor Biology, Vol 39 (2017)
Zhao et al. investigated the association between germline genetic polymorphisms in DPYD , the gene encoding dihydropyrimidine dehydrogenase, and (1) the risk of developing pediatric acute lymphoblastic leukemia and (2) outcome of acute lymphoblastic
Externí odkaz:
https://doaj.org/article/51ec12c55c3a4e29ba13920a88b3786e
Autor:
Ulrik N. Lassen, Martin Weisser, Birgit Bossenmaier, Francesca Michielin, Celine Adessi, Lori Steiner, Maitram Nguyen, Rajiv Dua, Suzana Vega-Harring, Ian James, Georgina Meneses-Lorente, Maurizio Ceppi, Marlene Thomas, Sabine Wilson, Jan H.M. Schellens, Sang-We Kim, Enriqueta Felip, Antonio Calles, Ji-Youn Han, Stefan Sleijfer, Maja J. De Jonge, Marlies H.G. Langenberg, Martijn P. Lolkema, Andres Cervantes, Tania Fleitas, Alvaro Taus, Maria Martinez-Garcia, Morten Mau-Sorensen, Emile E. Voest, Wolfgang Jacob, Didier Meulendijks
Purpose: This study investigated the safety, clinical activity, and target-associated biomarkers of lumretuzumab, a humanized, glycoengineered, anti-HER3 monoclonal antibody (mAb), in combination with the EGFR-blocking agents erlotinib or cetuximab i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::318985d039f3af8aedc62fa7c6e52f8e
https://doi.org/10.1158/1078-0432.c.6527064.v1
https://doi.org/10.1158/1078-0432.c.6527064.v1
Autor:
Ulrik N. Lassen, Martin Weisser, Jan H.M. Schellens, Birgit Bossenmaier, Keelara Abiraj, Francesca Michielin, Celine Adessi, Ian James, Georgina Meneses-Lorente, Maurizio Ceppi, Marlene Thomas, Morten Mau Soerensen, Stefan Sleijfer, Maja J. De Jonge, Andres Cervantes, Tania Fleitas Kanonnikoff, Marlies H.G. Langenberg, Emile E. Voest, Martijn P. Lolkema, Alvaro Taus, Maria Martinez-Garcia, Wolfgang Jacob, Didier Meulendijks
Figure 1 Mean ({plus minus}SD) serum lumretuzumab profiles following multiple ascending doses from 100 mg up to 2000 mg Figure 2 Percentage change in standardized uptake value maximum from baseline as assessed by FDG-PET at (a) Cycle 1 Day 14 and (b)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b72d52ddfd1a32c36eaa2245c001d135
https://doi.org/10.1158/1078-0432.22461363
https://doi.org/10.1158/1078-0432.22461363
Autor:
Ulrik N. Lassen, Martin Weisser, Birgit Bossenmaier, Francesca Michielin, Celine Adessi, Lori Steiner, Maitram Nguyen, Rajiv Dua, Suzana Vega-Harring, Ian James, Georgina Meneses-Lorente, Maurizio Ceppi, Marlene Thomas, Sabine Wilson, Jan H.M. Schellens, Sang-We Kim, Enriqueta Felip, Antonio Calles, Ji-Youn Han, Stefan Sleijfer, Maja J. De Jonge, Marlies H.G. Langenberg, Martijn P. Lolkema, Andres Cervantes, Tania Fleitas, Alvaro Taus, Maria Martinez-Garcia, Morten Mau-Sorensen, Emile E. Voest, Wolfgang Jacob, Didier Meulendijks
Supplementary Table 1 Downregulation of HER3 membrane protein expression in skin biopsies following treatment with lumretuzumab and cetuximab or erlotinib Supplementary Table 2 Change of tumor biomarkers in tumor biopsies following treatment with lum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::804d643b37a2cdf6fd277ce1fd5c048c
https://doi.org/10.1158/1078-0432.22468827
https://doi.org/10.1158/1078-0432.22468827
Autor:
Glenwood D. Goss, Mark DeMario, Ka Wang, David Geho, Tiantom Jarutat, Suzana M. Vega-Harring, Markus Roessler, Hua Zhong, Dean Bottino, Kathleen J. Schostack, Mary E. Simcox, Aaron R. Hansen, Derek J. Jonker, Jan H.M. Schellens, Morten Mau-Sorensen, Vaios Karanikas, Lilian L. Siu, Didier Meulendijks, Ulrik N. Lassen
Supplemental Figure S1 and Table S1. Figure S1: RG7212 phase I study flow diagram and treatment schema. Table S1. Summary of Fn14 Testing and Positivity Rate (IHC{greater than or equal to}1+) for the Most Commonly Screened Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e0ab408c3772903e1549f808a8c8771
https://doi.org/10.1158/1078-0432.22460889.v1
https://doi.org/10.1158/1078-0432.22460889.v1